Jadenu Sprinkle is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 1 US drug patent filed in 2017 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 23, 2023. Details of Jadenu Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) |
Expired
|
FDA has granted several exclusivities to Jadenu Sprinkle. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Jadenu Sprinkle, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Jadenu Sprinkle.
Exclusivity Information
Jadenu Sprinkle holds 3 exclusivities. All of its exclusivities have expired in 2023. Details of Jadenu Sprinkle's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-239) | Dec 12, 2021 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
US patents provide insights into the exclusivity only within the United States, but Jadenu Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Jadenu Sprinkle's family patents as well as insights into ongoing legal events on those patents.
Jadenu Sprinkle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Jadenu Sprinkle's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 23, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Jadenu Sprinkle Generic API suppliers:
Deferasirox is the generic name for the brand Jadenu Sprinkle. 19 different companies have already filed for the generic of Jadenu Sprinkle, with Alkem Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Jadenu Sprinkle's generic
Alternative Brands for Jadenu Sprinkle
Jadenu Sprinkle which is used for treating allergies and allergic reactions., has several other brand drugs using the same active ingredient (Deferasirox). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Deferasirox, Jadenu Sprinkle's active ingredient. Check the complete list of approved generic manufacturers for Jadenu Sprinkle
About Jadenu Sprinkle
Jadenu Sprinkle is a drug owned by Novartis Pharmaceuticals Corp. It is used for treating allergies and allergic reactions. Jadenu Sprinkle uses Deferasirox as an active ingredient. Jadenu Sprinkle was launched by Novartis in 2017.
Approval Date:
Jadenu Sprinkle was approved by FDA for market use on 18 May, 2017.
Active Ingredient:
Jadenu Sprinkle uses Deferasirox as the active ingredient. Check out other Drugs and Companies using Deferasirox ingredient
Treatment:
Jadenu Sprinkle is used for treating allergies and allergic reactions.
Dosage:
Jadenu Sprinkle is available in granule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 180MG | GRANULE | Prescription | ORAL |
| 360MG | GRANULE | Prescription | ORAL |
| 90MG | GRANULE | Prescription | ORAL |